Akari Therapeutics Reports $14.5 Million Net Loss and Financial Challenges in Latest 10-Q

Akari Therapeutics Plc reported significant financial challenges in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $14.5 million, a substantial increase from the $3.7 million loss reported in the same period the previous year. This increase was primarily driven by a $12.1 million non-cash impairment charge related to goodwill and other intangible assets, reflecting a reassessment of the company's asset values in light of a sustained decline in its market capitalization.

Total operating expenses for the first quarter of 2026 reached $15.8 million, compared to $3.5 million in the prior year, marking a 347% increase. Research and development expenses rose to $1.5 million, up 79% from $813,000 in the previous year, as the company intensified its focus on advancing its lead product candidate, AKTX-101. General and administrative expenses decreased by 20% to $2.2 million, attributed to lower stock-based compensation costs. The company’s accumulated deficit now stands at $279 million, with cash and restricted cash totaling $2.8 million, insufficient to fund operations beyond June 2026.

In terms of strategic developments, Akari has been focusing on advancing its pipeline of antibody-drug conjugates (ADCs), particularly AKTX-101, which is in preclinical development. The company has initiated good manufacturing practices (GMP) for AKTX-101 and is working towards clinical readiness, with plans to enter clinical trials by mid-2027. Additionally, Akari announced a change in the ratio of its American Depositary Shares (ADS) to ordinary shares, effective March 31, 2026, which now stands at one ADS representing 80,000 ordinary shares.

Operationally, Akari has not generated any revenue since its inception and continues to rely on external funding to support its research and development activities. The company is exploring various funding strategies, including private placements and public offerings, to secure the necessary capital for its ongoing operations. The filing indicates that the company is actively seeking additional funding to avoid potential disruptions to its development plans.

Looking ahead, Akari's management has expressed concerns about its ability to continue as a going concern, given the substantial losses and the need for additional financing. The company is evaluating its options for raising capital and is committed to advancing its ADC pipeline while managing its financial resources carefully. The outlook remains uncertain, with the potential for further operational and financial challenges as it navigates the complexities of drug development in the competitive biotechnology landscape.